Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis
As quantitative glucose 6-phosphate dehydrogenase deficiency (G6PDd) screening tools are evaluated in operational studies, questions remain as to whether they are cost-effective. Here, a cost-effectiveness analysis (CEA) was performed to estimate the Incremental Cost-effectiveness Ratio (ICER) of th...
Gespeichert in:
| Veröffentlicht in: | PLoS neglected tropical diseases 2022-03, Vol.16 (3), p.e0010325 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | e0010325 |
| container_title | PLoS neglected tropical diseases |
| container_volume | 16 |
| creator | Brito-Sousa, Jose Diego Peixoto, Henry M Devine, Angela Silva-Neto, Alexandre V Balieiro, Patricia C S Sampaio, Vanderson S Vitor-Silva, Sheila Mendes, Maxwell O Souza, Brenda K A Lacerda, Marcus V G Monteiro, Wuelton M |
| description | As quantitative glucose 6-phosphate dehydrogenase deficiency (G6PDd) screening tools are evaluated in operational studies, questions remain as to whether they are cost-effective. Here, a cost-effectiveness analysis (CEA) was performed to estimate the Incremental Cost-effectiveness Ratio (ICER) of the introduction of quantitative screening test to detect G6PDd among P. vivax carriers in two municipalities in the Brazilian Amazon.
This cost-effectiveness analysis evaluated the use of the Standard G6PD quantitative screening test in vivax malaria treatment units in two municipalities of the Brazilian Amazon. Using the perspective of the Brazilian public health system, the analysis was performed for the outcome 'PQ-associated hospitalization avoided', based on a decision tree model. The results indicated that the G6PDd screening strategy compared with the routine strategy was highly cost-effective, with an ICER of US$495 per additional hospitalization avoided, which represented less than 8% of one Brazilian gross domestic product per capita (US$6,822). The uncertainties evaluated in the sensitivity analysis did not significantly affect the ICER identified in the base-case.
This cost-effectiveness analysis showed the quantitative G6PD testing was effective in avoiding PQ-associated hospitalizations. The incorporation of G6PD screening is of paramount importance towards P. vivax malaria elimination in the Amazon to promote the safe use of primaquine and tafenoquine. |
| doi_str_mv | 10.1371/journal.pntd.0010325 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2651150456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A699910236</galeid><doaj_id>oai_doaj_org_article_1ec75f4b840948c2a492b3856ece5981</doaj_id><sourcerecordid>A699910236</sourcerecordid><originalsourceid>FETCH-LOGICAL-c591t-fdd53c6f0ea501e042b7592162dcafb327e3e85503c3272d43be83ebee0727343</originalsourceid><addsrcrecordid>eNp1Ul1v0zAUjRCIjcE_QGAJibd0_ogTmwekMmBMmsSE4NlynJvWVWJ3sVPR_XrcNZtaacgPtu495_jcq5NlbwmeEVaR85UfB6e72drFZoYxwYzyZ9kpkYzntGL8-cH7JHsVwgpjLrkgL7MTxhkthKSn2fYX6C7vbAvodtQu2qij3QC6LG--omAGAGfdAlmHbjodet_YsUcbu9F_0TohwcWwa8YloC-DvrOd1Q7Ne33n3Sc0R8aHmEPbgtmpOggB6WR6G2x4nb1odRfgzXSfZX--f_t98SO__nl5dTG_zg2XJOZt03BmyhaD5pgALmhdcUlJSRuj25rRChgIzjEz6U2bgtUgGNQAuEqjF-wse7_XXXc-qGlrQdGSE8JxwcuEuNojGq9Xaj3YXg9b5bVV9wU_LJQeojUdKAKm4m1RiwLLQhiqC0lrJngJBrgUJGl9nn4b6x4akxY06O5I9Ljj7FIt_EYJKai4F_gwCQz-doQQ_2N5Qi10cmVd65OY6W0wal5KKQmmbIeaPYFKp4HeGu-gtal-RPh4QFimaMRl8N0YrXfhGFjsgWbwIQzQPk5IsNrF88G12sVTTfFMtHeH23kkPeSR_QOIbeJr</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2651150456</pqid></control><display><type>article</type><title>Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><creator>Brito-Sousa, Jose Diego ; Peixoto, Henry M ; Devine, Angela ; Silva-Neto, Alexandre V ; Balieiro, Patricia C S ; Sampaio, Vanderson S ; Vitor-Silva, Sheila ; Mendes, Maxwell O ; Souza, Brenda K A ; Lacerda, Marcus V G ; Monteiro, Wuelton M</creator><contributor>Fuehrer, Hans-Peter</contributor><creatorcontrib>Brito-Sousa, Jose Diego ; Peixoto, Henry M ; Devine, Angela ; Silva-Neto, Alexandre V ; Balieiro, Patricia C S ; Sampaio, Vanderson S ; Vitor-Silva, Sheila ; Mendes, Maxwell O ; Souza, Brenda K A ; Lacerda, Marcus V G ; Monteiro, Wuelton M ; Fuehrer, Hans-Peter</creatorcontrib><description>As quantitative glucose 6-phosphate dehydrogenase deficiency (G6PDd) screening tools are evaluated in operational studies, questions remain as to whether they are cost-effective. Here, a cost-effectiveness analysis (CEA) was performed to estimate the Incremental Cost-effectiveness Ratio (ICER) of the introduction of quantitative screening test to detect G6PDd among P. vivax carriers in two municipalities in the Brazilian Amazon.
This cost-effectiveness analysis evaluated the use of the Standard G6PD quantitative screening test in vivax malaria treatment units in two municipalities of the Brazilian Amazon. Using the perspective of the Brazilian public health system, the analysis was performed for the outcome 'PQ-associated hospitalization avoided', based on a decision tree model. The results indicated that the G6PDd screening strategy compared with the routine strategy was highly cost-effective, with an ICER of US$495 per additional hospitalization avoided, which represented less than 8% of one Brazilian gross domestic product per capita (US$6,822). The uncertainties evaluated in the sensitivity analysis did not significantly affect the ICER identified in the base-case.
This cost-effectiveness analysis showed the quantitative G6PD testing was effective in avoiding PQ-associated hospitalizations. The incorporation of G6PD screening is of paramount importance towards P. vivax malaria elimination in the Amazon to promote the safe use of primaquine and tafenoquine.</description><identifier>ISSN: 1935-2735</identifier><identifier>ISSN: 1935-2727</identifier><identifier>EISSN: 1935-2735</identifier><identifier>DOI: 10.1371/journal.pntd.0010325</identifier><identifier>PMID: 35324892</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Antimalarials ; Antimalarials - therapeutic use ; Biology and Life Sciences ; Brazil ; Care and treatment ; Complications and side effects ; Cost analysis ; Cost benefit analysis ; Decision trees ; Diagnosis ; Dosage and administration ; Engineering and Technology ; Enzymes ; Females ; Glucose 6 phosphate dehydrogenase ; Glucose-6-phosphate dehydrogenase deficiency ; Glucosephosphate dehydrogenase ; Glucosephosphate Dehydrogenase Deficiency - diagnosis ; Hospitalization ; Human diseases ; Humans ; Information systems ; Malaria ; Malaria, Vivax - diagnosis ; Malaria, Vivax - drug therapy ; Males ; Medical screening ; Medicine and Health Sciences ; Methods ; Monte Carlo simulation ; Municipalities ; Patients ; People and places ; Phosphates ; Plasmodium vivax ; Primaquine ; Primaquine - therapeutic use ; Probability ; Public health ; Risk factors ; Sensitivity analysis ; Social Sciences ; Tafenoquine ; Tropical diseases ; Vector-borne diseases</subject><ispartof>PLoS neglected tropical diseases, 2022-03, Vol.16 (3), p.e0010325</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Brito-Sousa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Brito-Sousa et al 2022 Brito-Sousa et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c591t-fdd53c6f0ea501e042b7592162dcafb327e3e85503c3272d43be83ebee0727343</citedby><cites>FETCH-LOGICAL-c591t-fdd53c6f0ea501e042b7592162dcafb327e3e85503c3272d43be83ebee0727343</cites><orcidid>0000-0002-0848-1940</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982881/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982881/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2104,2930,23873,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35324892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Fuehrer, Hans-Peter</contributor><creatorcontrib>Brito-Sousa, Jose Diego</creatorcontrib><creatorcontrib>Peixoto, Henry M</creatorcontrib><creatorcontrib>Devine, Angela</creatorcontrib><creatorcontrib>Silva-Neto, Alexandre V</creatorcontrib><creatorcontrib>Balieiro, Patricia C S</creatorcontrib><creatorcontrib>Sampaio, Vanderson S</creatorcontrib><creatorcontrib>Vitor-Silva, Sheila</creatorcontrib><creatorcontrib>Mendes, Maxwell O</creatorcontrib><creatorcontrib>Souza, Brenda K A</creatorcontrib><creatorcontrib>Lacerda, Marcus V G</creatorcontrib><creatorcontrib>Monteiro, Wuelton M</creatorcontrib><title>Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis</title><title>PLoS neglected tropical diseases</title><addtitle>PLoS Negl Trop Dis</addtitle><description>As quantitative glucose 6-phosphate dehydrogenase deficiency (G6PDd) screening tools are evaluated in operational studies, questions remain as to whether they are cost-effective. Here, a cost-effectiveness analysis (CEA) was performed to estimate the Incremental Cost-effectiveness Ratio (ICER) of the introduction of quantitative screening test to detect G6PDd among P. vivax carriers in two municipalities in the Brazilian Amazon.
This cost-effectiveness analysis evaluated the use of the Standard G6PD quantitative screening test in vivax malaria treatment units in two municipalities of the Brazilian Amazon. Using the perspective of the Brazilian public health system, the analysis was performed for the outcome 'PQ-associated hospitalization avoided', based on a decision tree model. The results indicated that the G6PDd screening strategy compared with the routine strategy was highly cost-effective, with an ICER of US$495 per additional hospitalization avoided, which represented less than 8% of one Brazilian gross domestic product per capita (US$6,822). The uncertainties evaluated in the sensitivity analysis did not significantly affect the ICER identified in the base-case.
This cost-effectiveness analysis showed the quantitative G6PD testing was effective in avoiding PQ-associated hospitalizations. The incorporation of G6PD screening is of paramount importance towards P. vivax malaria elimination in the Amazon to promote the safe use of primaquine and tafenoquine.</description><subject>Analysis</subject><subject>Antimalarials</subject><subject>Antimalarials - therapeutic use</subject><subject>Biology and Life Sciences</subject><subject>Brazil</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Cost analysis</subject><subject>Cost benefit analysis</subject><subject>Decision trees</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Engineering and Technology</subject><subject>Enzymes</subject><subject>Females</subject><subject>Glucose 6 phosphate dehydrogenase</subject><subject>Glucose-6-phosphate dehydrogenase deficiency</subject><subject>Glucosephosphate dehydrogenase</subject><subject>Glucosephosphate Dehydrogenase Deficiency - diagnosis</subject><subject>Hospitalization</subject><subject>Human diseases</subject><subject>Humans</subject><subject>Information systems</subject><subject>Malaria</subject><subject>Malaria, Vivax - diagnosis</subject><subject>Malaria, Vivax - drug therapy</subject><subject>Males</subject><subject>Medical screening</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Monte Carlo simulation</subject><subject>Municipalities</subject><subject>Patients</subject><subject>People and places</subject><subject>Phosphates</subject><subject>Plasmodium vivax</subject><subject>Primaquine</subject><subject>Primaquine - therapeutic use</subject><subject>Probability</subject><subject>Public health</subject><subject>Risk factors</subject><subject>Sensitivity analysis</subject><subject>Social Sciences</subject><subject>Tafenoquine</subject><subject>Tropical diseases</subject><subject>Vector-borne diseases</subject><issn>1935-2735</issn><issn>1935-2727</issn><issn>1935-2735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNp1Ul1v0zAUjRCIjcE_QGAJibd0_ogTmwekMmBMmsSE4NlynJvWVWJ3sVPR_XrcNZtaacgPtu495_jcq5NlbwmeEVaR85UfB6e72drFZoYxwYzyZ9kpkYzntGL8-cH7JHsVwgpjLrkgL7MTxhkthKSn2fYX6C7vbAvodtQu2qij3QC6LG--omAGAGfdAlmHbjodet_YsUcbu9F_0TohwcWwa8YloC-DvrOd1Q7Ne33n3Sc0R8aHmEPbgtmpOggB6WR6G2x4nb1odRfgzXSfZX--f_t98SO__nl5dTG_zg2XJOZt03BmyhaD5pgALmhdcUlJSRuj25rRChgIzjEz6U2bgtUgGNQAuEqjF-wse7_XXXc-qGlrQdGSE8JxwcuEuNojGq9Xaj3YXg9b5bVV9wU_LJQeojUdKAKm4m1RiwLLQhiqC0lrJngJBrgUJGl9nn4b6x4akxY06O5I9Ljj7FIt_EYJKai4F_gwCQz-doQQ_2N5Qi10cmVd65OY6W0wal5KKQmmbIeaPYFKp4HeGu-gtal-RPh4QFimaMRl8N0YrXfhGFjsgWbwIQzQPk5IsNrF88G12sVTTfFMtHeH23kkPeSR_QOIbeJr</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Brito-Sousa, Jose Diego</creator><creator>Peixoto, Henry M</creator><creator>Devine, Angela</creator><creator>Silva-Neto, Alexandre V</creator><creator>Balieiro, Patricia C S</creator><creator>Sampaio, Vanderson S</creator><creator>Vitor-Silva, Sheila</creator><creator>Mendes, Maxwell O</creator><creator>Souza, Brenda K A</creator><creator>Lacerda, Marcus V G</creator><creator>Monteiro, Wuelton M</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T2</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0848-1940</orcidid></search><sort><creationdate>20220301</creationdate><title>Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis</title><author>Brito-Sousa, Jose Diego ; Peixoto, Henry M ; Devine, Angela ; Silva-Neto, Alexandre V ; Balieiro, Patricia C S ; Sampaio, Vanderson S ; Vitor-Silva, Sheila ; Mendes, Maxwell O ; Souza, Brenda K A ; Lacerda, Marcus V G ; Monteiro, Wuelton M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c591t-fdd53c6f0ea501e042b7592162dcafb327e3e85503c3272d43be83ebee0727343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Antimalarials</topic><topic>Antimalarials - therapeutic use</topic><topic>Biology and Life Sciences</topic><topic>Brazil</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Cost analysis</topic><topic>Cost benefit analysis</topic><topic>Decision trees</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Engineering and Technology</topic><topic>Enzymes</topic><topic>Females</topic><topic>Glucose 6 phosphate dehydrogenase</topic><topic>Glucose-6-phosphate dehydrogenase deficiency</topic><topic>Glucosephosphate dehydrogenase</topic><topic>Glucosephosphate Dehydrogenase Deficiency - diagnosis</topic><topic>Hospitalization</topic><topic>Human diseases</topic><topic>Humans</topic><topic>Information systems</topic><topic>Malaria</topic><topic>Malaria, Vivax - diagnosis</topic><topic>Malaria, Vivax - drug therapy</topic><topic>Males</topic><topic>Medical screening</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Monte Carlo simulation</topic><topic>Municipalities</topic><topic>Patients</topic><topic>People and places</topic><topic>Phosphates</topic><topic>Plasmodium vivax</topic><topic>Primaquine</topic><topic>Primaquine - therapeutic use</topic><topic>Probability</topic><topic>Public health</topic><topic>Risk factors</topic><topic>Sensitivity analysis</topic><topic>Social Sciences</topic><topic>Tafenoquine</topic><topic>Tropical diseases</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brito-Sousa, Jose Diego</creatorcontrib><creatorcontrib>Peixoto, Henry M</creatorcontrib><creatorcontrib>Devine, Angela</creatorcontrib><creatorcontrib>Silva-Neto, Alexandre V</creatorcontrib><creatorcontrib>Balieiro, Patricia C S</creatorcontrib><creatorcontrib>Sampaio, Vanderson S</creatorcontrib><creatorcontrib>Vitor-Silva, Sheila</creatorcontrib><creatorcontrib>Mendes, Maxwell O</creatorcontrib><creatorcontrib>Souza, Brenda K A</creatorcontrib><creatorcontrib>Lacerda, Marcus V G</creatorcontrib><creatorcontrib>Monteiro, Wuelton M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PLoS neglected tropical diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brito-Sousa, Jose Diego</au><au>Peixoto, Henry M</au><au>Devine, Angela</au><au>Silva-Neto, Alexandre V</au><au>Balieiro, Patricia C S</au><au>Sampaio, Vanderson S</au><au>Vitor-Silva, Sheila</au><au>Mendes, Maxwell O</au><au>Souza, Brenda K A</au><au>Lacerda, Marcus V G</au><au>Monteiro, Wuelton M</au><au>Fuehrer, Hans-Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis</atitle><jtitle>PLoS neglected tropical diseases</jtitle><addtitle>PLoS Negl Trop Dis</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>16</volume><issue>3</issue><spage>e0010325</spage><pages>e0010325-</pages><issn>1935-2735</issn><issn>1935-2727</issn><eissn>1935-2735</eissn><abstract>As quantitative glucose 6-phosphate dehydrogenase deficiency (G6PDd) screening tools are evaluated in operational studies, questions remain as to whether they are cost-effective. Here, a cost-effectiveness analysis (CEA) was performed to estimate the Incremental Cost-effectiveness Ratio (ICER) of the introduction of quantitative screening test to detect G6PDd among P. vivax carriers in two municipalities in the Brazilian Amazon.
This cost-effectiveness analysis evaluated the use of the Standard G6PD quantitative screening test in vivax malaria treatment units in two municipalities of the Brazilian Amazon. Using the perspective of the Brazilian public health system, the analysis was performed for the outcome 'PQ-associated hospitalization avoided', based on a decision tree model. The results indicated that the G6PDd screening strategy compared with the routine strategy was highly cost-effective, with an ICER of US$495 per additional hospitalization avoided, which represented less than 8% of one Brazilian gross domestic product per capita (US$6,822). The uncertainties evaluated in the sensitivity analysis did not significantly affect the ICER identified in the base-case.
This cost-effectiveness analysis showed the quantitative G6PD testing was effective in avoiding PQ-associated hospitalizations. The incorporation of G6PD screening is of paramount importance towards P. vivax malaria elimination in the Amazon to promote the safe use of primaquine and tafenoquine.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>35324892</pmid><doi>10.1371/journal.pntd.0010325</doi><orcidid>https://orcid.org/0000-0002-0848-1940</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-2735 |
| ispartof | PLoS neglected tropical diseases, 2022-03, Vol.16 (3), p.e0010325 |
| issn | 1935-2735 1935-2727 1935-2735 |
| language | eng |
| recordid | cdi_plos_journals_2651150456 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Public Library of Science (PLoS); PubMed Central |
| subjects | Analysis Antimalarials Antimalarials - therapeutic use Biology and Life Sciences Brazil Care and treatment Complications and side effects Cost analysis Cost benefit analysis Decision trees Diagnosis Dosage and administration Engineering and Technology Enzymes Females Glucose 6 phosphate dehydrogenase Glucose-6-phosphate dehydrogenase deficiency Glucosephosphate dehydrogenase Glucosephosphate Dehydrogenase Deficiency - diagnosis Hospitalization Human diseases Humans Information systems Malaria Malaria, Vivax - diagnosis Malaria, Vivax - drug therapy Males Medical screening Medicine and Health Sciences Methods Monte Carlo simulation Municipalities Patients People and places Phosphates Plasmodium vivax Primaquine Primaquine - therapeutic use Probability Public health Risk factors Sensitivity analysis Social Sciences Tafenoquine Tropical diseases Vector-borne diseases |
| title | Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T05%3A45%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-life%20quantitative%20G6PD%20screening%20in%20Plasmodium%20vivax%20patients%20in%20the%20Brazilian%20Amazon:%20A%20cost-effectiveness%20analysis&rft.jtitle=PLoS%20neglected%20tropical%20diseases&rft.au=Brito-Sousa,%20Jose%20Diego&rft.date=2022-03-01&rft.volume=16&rft.issue=3&rft.spage=e0010325&rft.pages=e0010325-&rft.issn=1935-2735&rft.eissn=1935-2735&rft_id=info:doi/10.1371/journal.pntd.0010325&rft_dat=%3Cgale_plos_%3EA699910236%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2651150456&rft_id=info:pmid/35324892&rft_galeid=A699910236&rft_doaj_id=oai_doaj_org_article_1ec75f4b840948c2a492b3856ece5981&rfr_iscdi=true |